Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$16.78 USD

16.78
1,280,592

+0.73 (4.55%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $16.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Earnings Season Could Be Great for Neogen (NEOG)

Neogen (NEOG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Healthy Top-Line Growth Aid Jabil's (JBL) Q2 Earnings?

Jabil (JBL) is likely to witness top-line expansion backed by the company's continuous innovation approach, favorable demand trends and excellent operational execution.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Neogen's (NEOG) New Launches Aid, Margin Pressure Stays

Neogen (NEOG) continues to see rising revenues from the Food Safety business.

ICU Medical (ICUI) Beats Q4 Earnings Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.

Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up

Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.

Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase

Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.

Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up

Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down

Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.

QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down

Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop

Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.